Crispr Therapeutics Stock Price, News & Analysis (NASDAQ:CRSP)

$41.16 -0.45 (-1.08 %)
(As of 02/22/2018 10:00 AM ET)
Previous Close$41.16
Today's Range$41.09 - $43.44
52-Week Range$13.50 - $45.00
Volume1.56 million shs
Average Volume1.04 million shs
Market Capitalization$1.91 billion
P/E Ratio-31.16
Dividend YieldN/A
Beta9.84

About Crispr Therapeutics (NASDAQ:CRSP)

Crispr Therapeutics logoCrispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-61-228-7800

Debt

Debt-to-Equity RatioN/A
Current Ratio21.35%
Quick Ratio21.35%

Price-To-Earnings

Trailing P/E Ratio-31.1626427072522
Forward P/E Ratio-17.01
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.16 million
Price / Sales366.05
Cash FlowN/A
Price / CashN/A
Book Value$5.85 per share
Price / Book7.04

Profitability

Trailing EPS($1.32)
Net Income$-23,170,000.00
Net Margins-466.58%
Return on Equity-38.42%
Return on Assets-25.26%

Miscellaneous

Employees93
Outstanding Shares45,890,000

Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

What is Crispr Therapeutics' stock symbol?

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

How were Crispr Therapeutics' earnings last quarter?

Crispr Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.02. The firm earned $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business's revenue was up 54.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.77) EPS. View Crispr Therapeutics' Earnings History.

When will Crispr Therapeutics make its next earnings announcement?

Crispr Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March, 9th 2018. View Earnings Estimates for Crispr Therapeutics.

Where is Crispr Therapeutics' stock going? Where will Crispr Therapeutics' stock price be in 2018?

6 brokers have issued twelve-month price targets for Crispr Therapeutics' shares. Their predictions range from $16.00 to $29.00. On average, they anticipate Crispr Therapeutics' stock price to reach $22.81 in the next twelve months. View Analyst Ratings for Crispr Therapeutics.

What are Wall Street analysts saying about Crispr Therapeutics stock?

Here are some recent quotes from research analysts about Crispr Therapeutics stock:

  • 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (1/25/2018)
  • 2. Cann analysts commented, "CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018." (12/10/2017)
  • 3. Chardan Capital analysts commented, "We calculated the CRISPR sector enterprise value (EV) by discounting Chardan target sector EVs of companies in the AAV (assumed 3 years ahead) and small RNA (assumed 3 years ahead) gene therapy sectors; we applied a discount rate of 20%, which we believe is reasonable for preclinical biotech firms. Giving CRSP a CRISPR sector valuation distribution of 15% of the calculated CRISPR sector EV (based on our view of the firm’s relative IP weakness balanced by potential first entry of a CRISPR therapy into the clinic) and adding $272.3 mm in cash, we project a CRSP market cap range of $866 mm-$901 mm." (8/14/2017)

Who are some of Crispr Therapeutics' key competitors?

Who are Crispr Therapeutics' key executives?

Crispr Therapeutics' management team includes the folowing people:

  • Rodger Novak M.D., Chairman of the Board of Directors, President, Founder (Age 49)
  • Samarth Kulkarni Ph.D., Chief Executive Officer (Age 38)
  • Kala Subramanian Ph.D., Senior Vice President - Strategic Development and Operations (Age 49)
  • Megan Wherry Menner, Senior Vice President of Human Resources
  • Sven Ante Lundberg M.D., Chief Scientific Officer (Age 53)
  • Tony Ho, Head of Research and Development
  • Jim Kasinger, General Counsel, Secretary to the Board of Directors
  • Tyler M. Dylan-Hyde J.D., Ph.D., Chief Legal Officer (Age 55)
  • Jon Terrett Ph.D., Head of Immuno-Oncology Research and Translation
  • Ali Behbahani M.D., Independent Director (Age 40)

When did Crispr Therapeutics IPO?

(crsp) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who owns Crispr Therapeutics stock?

Crispr Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include CELGENE CORP (9.10%), CELGENE CORP (8.10%), Farallon Capital Management LLC (1.87%), Franklin Resources Inc. (1.73%), Global Thematic Partners LLC (1.38%) and BlackRock Inc. (1.20%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Corp /De/ Celgene, Kurt Von Emster, Rodger Novak, Samarth Kulkarni, Simeon George, Thomas Woiwode and Tyler Dylan-Hyde. View Institutional Ownership Trends for Crispr Therapeutics.

Who sold Crispr Therapeutics stock? Who is selling Crispr Therapeutics stock?

Crispr Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Corp /De/ Celgene, Kurt Von Emster, Rodger Novak, Samarth Kulkarni, Thomas Woiwode and Tyler Dylan-Hyde. View Insider Buying and Selling for Crispr Therapeutics.

Who bought Crispr Therapeutics stock? Who is buying Crispr Therapeutics stock?

Crispr Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, BlackRock Inc., Opaleye Management Inc., Capital Advisors Inc. OK, Allianz Asset Management GmbH, Franklin Resources Inc., Global Thematic Partners LLC and Essex Investment Management Co. LLC. Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer, Corp /De/ Celgene and Simeon George. View Insider Buying and Selling for Crispr Therapeutics.

How do I buy Crispr Therapeutics stock?

Shares of Crispr Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Crispr Therapeutics' stock price today?

One share of Crispr Therapeutics stock can currently be purchased for approximately $41.16.

How big of a company is Crispr Therapeutics?

Crispr Therapeutics has a market capitalization of $1.91 billion and generates $5.16 million in revenue each year. The company earns $-23,170,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Crispr Therapeutics employs 93 workers across the globe.

How can I contact Crispr Therapeutics?

Crispr Therapeutics' mailing address is AESCHENVORSTADT 36, BASEL V8, 4051. The company can be reached via phone at 41-61-228-7800.


MarketBeat Community Rating for Crispr Therapeutics (CRSP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Crispr Therapeutics (NASDAQ:CRSP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.502.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.81$22.81$22.38$21.92
Price Target Upside: 32.41% downside32.41% downside28.22% upside14.03% upside

Crispr Therapeutics (NASDAQ:CRSP) Consensus Price Target History

Price Target History for Crispr Therapeutics (NASDAQ:CRSP)

Crispr Therapeutics (NASDAQ:CRSP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2018SunTrust BanksUpgradeHold -> BuyHighView Rating Details
1/10/2018Piper Jaffray CompaniesReiterated RatingBuy$39.00 -> $22.75LowView Rating Details
12/21/2017OppenheimerReiterated RatingHoldHighView Rating Details
12/10/2017CannReiterated RatingHoldHighView Rating Details
9/8/2017BarclaysReiterated RatingBuy$29.00LowView Rating Details
8/14/2017Chardan CapitalReiterated RatingBuyMediumView Rating Details
11/15/2016CitigroupInitiated CoverageNeutral$19.00N/AView Rating Details
11/14/2016GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Crispr Therapeutics (NASDAQ:CRSP) Earnings History and Estimates Chart

Earnings by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Crispr Therapeutics (NASDAQ CRSP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2018        
11/8/2017Q3($0.60)($0.62)$3.61 million$2.39 millionViewN/AView Earnings Details
8/10/20176/30/2017($0.62)($0.56)$3.29 million$3.60 millionViewN/AView Earnings Details
5/11/20173/31/2017($0.60)($0.54)$2.70 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.38)($0.40)$2.34 millionViewN/AView Earnings Details
11/22/2016Q3 2016($2.77)$1.55 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Crispr Therapeutics (NASDAQ:CRSP) Earnings Estimates

2018 EPS Consensus Estimate: ($3.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.67)($0.67)($0.67)
Q2 20181($0.67)($0.67)($0.67)
Q3 20181($0.72)($0.72)($0.72)
Q4 20181($1.01)($1.01)($1.01)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Crispr Therapeutics (NASDAQ:CRSP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Crispr Therapeutics (NASDAQ CRSP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 39.98%
Institutional Ownership Percentage: 24.55%
Insider Trades by Quarter for Crispr Therapeutics (NASDAQ:CRSP)
Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Crispr Therapeutics (NASDAQ CRSP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018Tyler Dylan-HydeInsiderSell66,000$28.03$1,849,980.0025,204View SEC Filing  
1/5/2018Aktiengesellschaft BayerMajor ShareholderBuy527,472$22.75$11,999,988.00View SEC Filing  
1/5/2018Kurt Von EmsterDirectorSell92,337$26.96$2,489,405.52View SEC Filing  
1/2/2018Kurt Von EmsterDirectorSell37,754$26.76$1,010,297.04View SEC Filing  
1/2/2018Tyler Dylan-HydeInsiderSell38,000$21.64$822,320.0070,204View SEC Filing  
12/29/2017Tyler Dylan-HydeInsiderSell31,000$22.72$704,320.00View SEC Filing  
12/28/2017Tyler Dylan-HydeInsiderSell700$21.75$15,225.00115,904View SEC Filing  
12/22/2017Thomas WoiwodeDirectorSell3,059$20.29$62,067.114,959View SEC Filing  
12/22/2017Tyler Dylan-HydeInsiderSell15,000$20.55$308,250.00115,204View SEC Filing  
12/15/2017Tyler Dylan-HydeInsiderSell15,000$18.90$283,500.00130,204View SEC Filing  
12/4/2017Corp /De/ CelgeneMajor ShareholderSell1,112,446$18.98$21,114,225.08View SEC Filing  
12/1/2017Corp /De/ CelgeneMajor ShareholderSell87,991$19.10$1,680,628.10View SEC Filing  
11/29/2017Corp /De/ CelgeneMajor ShareholderSell4,263$19.25$82,062.75View SEC Filing  
11/27/2017Corp /De/ CelgeneMajor ShareholderSell27,990$19.75$552,802.50View SEC Filing  
11/27/2017Thomas WoiwodeDirectorSell200$20.24$4,048.008,218View SEC Filing  
11/24/2017Corp /De/ CelgeneMajor ShareholderSell26,010$20.00$520,200.00View SEC Filing  
11/24/2017Thomas WoiwodeDirectorSell1,700$20.21$34,357.008,218View SEC Filing  
11/22/2017Corp /De/ CelgeneMajor ShareholderSell256,000$19.76$5,058,560.00View SEC Filing  
11/20/2017Corp /De/ CelgeneMajor ShareholderSell158,718$19.02$3,018,816.36View SEC Filing  
11/17/2017Corp /De/ CelgeneMajor ShareholderSell51,282$18.44$945,640.08View SEC Filing  
11/15/2017Corp /De/ CelgeneMajor ShareholderSell15,000$17.67$265,050.00View SEC Filing  
11/13/2017Corp /De/ CelgeneMajor ShareholderSell65,093$17.76$1,156,051.68View SEC Filing  
11/10/2017Corp /De/ CelgeneMajor ShareholderSell10,000$17.28$172,800.00View SEC Filing  
11/8/2017Corp /De/ CelgeneMajor ShareholderSell16,875$18.06$304,762.50View SEC Filing  
11/6/2017Corp /De/ CelgeneMajor ShareholderSell79,327$18.89$1,498,487.03View SEC Filing  
11/3/2017Corp /De/ CelgeneMajor ShareholderSell22,759$19.10$434,696.90View SEC Filing  
9/5/2017Rodger NovakCEOSell18,470$20.76$383,437.201,148,007View SEC Filing  
8/30/2017Rodger NovakCEOSell75,795$20.25$1,534,848.751,232,697View SEC Filing  
8/30/2017Samarth KulkarniInsiderSell27,154$20.08$545,252.32110,893View SEC Filing  
8/28/2017Kurt Von EmsterDirectorSell88,011$19.79$1,741,737.69View SEC Filing  
8/25/2017Kurt Von EmsterDirectorSell22,781$19.42$442,407.02View SEC Filing  
8/23/2017Kurt Von EmsterDirectorSell17,989$18.53$333,336.17View SEC Filing  
8/21/2017Kurt Von EmsterDirectorSell3,150$18.52$58,338.00View SEC Filing  
8/17/2017Kurt Von EmsterDirectorSell34,141$19.06$650,727.46View SEC Filing  
8/15/2017Kurt Von EmsterDirectorSell55,569$19.59$1,088,596.71View SEC Filing  
8/8/2017Kurt Von EmsterDirectorSell35,473$18.63$660,861.99View SEC Filing  
8/8/2017Tyler Dylan-HydeInsiderSell15,000$18.57$278,550.00167,727View SEC Filing  
8/4/2017Kurt Von EmsterDirectorSell50,477$17.81$898,995.37View SEC Filing  
8/1/2017Kurt Von EmsterDirectorSell5,512$17.51$96,515.12View SEC Filing  
7/28/2017Kurt Von EmsterDirectorSell41,312$17.63$728,330.56View SEC Filing  
7/26/2017Kurt Von EmsterDirectorSell32,930$17.60$579,568.00View SEC Filing  
7/14/2017Kurt Von EmsterDirectorSell69,859$16.84$1,176,425.56View SEC Filing  
7/12/2017Kurt Von EmsterDirectorSell31,992$16.56$529,787.52View SEC Filing  
7/5/2017Kurt Von EmsterDirectorSell4,254$16.26$69,170.04View SEC Filing  
6/29/2017Kurt Von EmsterDirectorSell43,202$16.90$730,113.80View SEC Filing  
6/27/2017Kurt Von EmsterDirectorSell81,435$17.08$1,390,909.80View SEC Filing  
6/23/2017Kurt Von EmsterDirectorSell32,368$16.23$525,332.64View SEC Filing  
6/22/2017Rodger NovakCEOSell10,825$15.37$166,380.251,225,830View SEC Filing  
6/21/2017Rodger NovakCEOSell30,222$15.01$453,632.221,230,397View SEC Filing  
6/9/2017Rodger NovakCEOSell5,303$15.02$79,651.061,219,208View SEC Filing  
5/30/2017Rodger NovakCEOSell3,650$15.02$54,823.001,218,655View SEC Filing  
5/17/2017Rodger NovakCEOSell50,000$16.26$813,000.001,239,082View SEC Filing  
5/5/2017Rodger NovakCEOSell616$16.92$10,422.721,215,621View SEC Filing  
5/4/2017Rodger NovakCEOSell49,384$16.30$804,959.201,230,929View SEC Filing  
4/28/2017Tyler Dylan-HydeInsiderSell21,639$16.78$363,102.42180,495View SEC Filing  
4/27/2017Samarth KulkarniInsiderSell5,481$16.76$91,861.56137,322View SEC Filing  
4/25/2017Samarth KulkarniInsiderSell11,615$16.78$194,899.70137,047View SEC Filing  
4/20/2017Rodger NovakCEOSell50,000$17.88$894,000.001,262,711View SEC Filing  
4/20/2017Tyler Dylan-HydeInsiderSell10,177$17.71$180,234.67200,274View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/24/2016Simeon GeorgeDirectorBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Crispr Therapeutics (NASDAQ CRSP) News Headlines

Source:
DateHeadline
CRISPR Therapeutics to Participate in Four Upcoming Investor ConferencesCRISPR Therapeutics to Participate in Four Upcoming Investor Conferences
finance.yahoo.com - February 21 at 9:34 AM
Zacks: Analysts Anticipate Crispr Therapeutics AG (CRSP) Will Announce Quarterly Sales of $2.10 MillionZacks: Analysts Anticipate Crispr Therapeutics AG (CRSP) Will Announce Quarterly Sales of $2.10 Million
www.americanbankingnews.com - February 18 at 6:56 AM
 Brokerages Anticipate Crispr Therapeutics AG (CRSP) Will Announce Earnings of -$0.71 Per Share Brokerages Anticipate Crispr Therapeutics AG (CRSP) Will Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - February 16 at 1:16 AM
CRISPR Therapeutics Announces Transition of Bill Lundberg, MDCRISPR Therapeutics Announces Transition of Bill Lundberg, MD
finance.yahoo.com - February 9 at 9:12 AM
Why Crispr Therapeutics AG Stock Bolted Higher in JanuaryWhy Crispr Therapeutics AG Stock Bolted Higher in January
www.fool.com - February 8 at 1:42 PM
Crispr Therapeutics AG (CRSP) Expected to Announce Quarterly Sales of $2.10 MillionCrispr Therapeutics AG (CRSP) Expected to Announce Quarterly Sales of $2.10 Million
www.americanbankingnews.com - February 1 at 10:18 AM
Crispr Therapeutics AG (CRSP) Major Shareholder Aktiengesellschaft Bayer Purchases 527,472 SharesCrispr Therapeutics AG (CRSP) Major Shareholder Aktiengesellschaft Bayer Purchases 527,472 Shares
www.americanbankingnews.com - January 30 at 3:12 PM
AKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With Hope, ARGX SoarsAKCA ON The Move, MNLO Makes A Mark, OBSV Looks Ahead With Hope, ARGX Soars
www.nasdaq.com - January 30 at 9:35 AM
 Brokerages Expect Crispr Therapeutics AG (CRSP) to Announce -$0.71 Earnings Per Share Brokerages Expect Crispr Therapeutics AG (CRSP) to Announce -$0.71 Earnings Per Share
www.americanbankingnews.com - January 30 at 1:16 AM
Crispr Therapeutics AG (CRSP) Given Average Recommendation of "Buy" by AnalystsCrispr Therapeutics AG (CRSP) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 29 at 1:46 AM
Crispr Therapeutics (CRSP) Raised to Strong-Buy at BidaskClubCrispr Therapeutics (CRSP) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - January 28 at 9:32 AM
Crispr Therapeutics (CRSP) Stock Rating Lowered by Zacks Investment ResearchCrispr Therapeutics (CRSP) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 25 at 9:06 PM
FY2019 EPS Estimates for Crispr Therapeutics AG (CRSP) Lowered by SunTrust BanksFY2019 EPS Estimates for Crispr Therapeutics AG (CRSP) Lowered by SunTrust Banks
www.americanbankingnews.com - January 25 at 3:28 PM
Crispr Therapeutics AG Expected to Post FY2022 Earnings of ($3.83) Per Share (CRSP)Crispr Therapeutics AG Expected to Post FY2022 Earnings of ($3.83) Per Share (CRSP)
www.americanbankingnews.com - January 24 at 9:02 PM
Heres Whats Driving Crispr Therapeutics AG Higher TodayHere's What's Driving Crispr Therapeutics AG Higher Today
www.fool.com - January 23 at 1:26 PM
Chinese scientists used Crispr gene editing on 86 human patientsChinese scientists used Crispr gene editing on 86 human patients
finance.yahoo.com - January 23 at 8:18 AM
[$$] China, Unhampered by Rules, Races Ahead in Gene-Editing Trials[$$] China, Unhampered by Rules, Races Ahead in Gene-Editing Trials
finance.yahoo.com - January 22 at 5:51 PM
Iqvia (IQV) versus Crispr Therapeutics (CRSP) Critical ContrastIqvia (IQV) versus Crispr Therapeutics (CRSP) Critical Contrast
www.americanbankingnews.com - January 19 at 5:32 PM
Insider Selling: Crispr Therapeutics AG (CRSP) Insider Sells 66,000 Shares of StockInsider Selling: Crispr Therapeutics AG (CRSP) Insider Sells 66,000 Shares of Stock
www.americanbankingnews.com - January 18 at 6:34 PM
$2.10 Million in Sales Expected for Crispr Therapeutics AG (CRSP) This Quarter$2.10 Million in Sales Expected for Crispr Therapeutics AG (CRSP) This Quarter
www.americanbankingnews.com - January 15 at 10:40 PM
Rosetta Genomics (ROSG) & Crispr Therapeutics (CRSP) Head to Head ComparisonRosetta Genomics (ROSG) & Crispr Therapeutics (CRSP) Head to Head Comparison
www.americanbankingnews.com - January 15 at 9:16 PM
Crispr Therapeutics AG (CRSP) Expected to Post Earnings of -$0.74 Per ShareCrispr Therapeutics AG (CRSP) Expected to Post Earnings of -$0.74 Per Share
www.americanbankingnews.com - January 13 at 3:28 AM
Kurt Von Emster Sells 92,337 Shares of Crispr Therapeutics AG (CRSP) StockKurt Von Emster Sells 92,337 Shares of Crispr Therapeutics AG (CRSP) Stock
www.americanbankingnews.com - January 9 at 6:50 PM
Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS RatingStocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating
finance.yahoo.com - January 8 at 5:43 PM
Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless - Motley FoolUh-Oh! CRISPR Gene-Editing Stocks May Be Worthless - Motley Fool
www.fool.com - January 8 at 8:09 AM
Uh-Oh! CRISPR Gene-Editing Stocks May Be WorthlessUh-Oh! CRISPR Gene-Editing Stocks May Be Worthless
finance.yahoo.com - January 8 at 8:09 AM
Crispr Therapeutics Sees Unusually Large Options Volume (CRSP)Crispr Therapeutics Sees Unusually Large Options Volume (CRSP)
www.americanbankingnews.com - January 7 at 2:40 AM
Investors Cheer Secondary Offering for Gene-Editing FirmInvestors Cheer Secondary Offering for Gene-Editing Firm
finance.yahoo.com - January 5 at 5:19 PM
Heres What Pushed Crispr Therapeutics AG Up 23.6% in December - Motley FoolHere's What Pushed Crispr Therapeutics AG Up 23.6% in December - Motley Fool
www.fool.com - January 5 at 9:19 AM
Tyler Dylan-Hyde Sells 38,000 Shares of Crispr Therapeutics AG (CRSP) StockTyler Dylan-Hyde Sells 38,000 Shares of Crispr Therapeutics AG (CRSP) Stock
www.americanbankingnews.com - January 4 at 9:28 PM
Kurt Von Emster Sells 37,754 Shares of Crispr Therapeutics AG (CRSP) StockKurt Von Emster Sells 37,754 Shares of Crispr Therapeutics AG (CRSP) Stock
www.americanbankingnews.com - January 4 at 7:30 PM
Heres What Pushed Crispr Therapeutics AG Up 23.6% in DecemberHere's What Pushed Crispr Therapeutics AG Up 23.6% in December
www.fool.com - January 4 at 2:11 PM
CRISPR Therapeutics - Corporate Update To Jump Start 2018 - Seeking AlphaCRISPR Therapeutics - Corporate Update To Jump Start 2018 - Seeking Alpha
seekingalpha.com - January 4 at 9:13 AM
Crispr Therapeutics AG (CRSP) Given Consensus Rating of "Hold" by BrokeragesCrispr Therapeutics AG (CRSP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 4 at 2:26 AM
CRISPR Therapeutics Announces Proposed Public Offering of ... - GlobeNewswire (press release)CRISPR Therapeutics Announces Proposed Public Offering of ... - GlobeNewswire (press release)
globenewswire.com - January 3 at 8:27 AM
Tyler Dylan-Hyde Sells 700 Shares of Crispr Therapeutics AG (CRSP) StockTyler Dylan-Hyde Sells 700 Shares of Crispr Therapeutics AG (CRSP) Stock
www.americanbankingnews.com - January 2 at 7:58 PM
Crispr Therapeutics AG (CRSP) Insider Tyler Dylan-Hyde Sells 31,000 SharesCrispr Therapeutics AG (CRSP) Insider Tyler Dylan-Hyde Sells 31,000 Shares
www.americanbankingnews.com - January 2 at 6:32 PM
Reviewing Crispr Therapeutics (CRSP) and Incyte (INCY)Reviewing Crispr Therapeutics (CRSP) and Incyte (INCY)
www.americanbankingnews.com - January 1 at 9:26 AM
Insider Selling: Crispr Therapeutics AG (CRSP) Director Sells 3,059 Shares of StockInsider Selling: Crispr Therapeutics AG (CRSP) Director Sells 3,059 Shares of Stock
www.americanbankingnews.com - December 28 at 5:10 PM
Crispr Therapeutics AG (CRSP) Insider Tyler Dylan-Hyde Sells 15,000 SharesCrispr Therapeutics AG (CRSP) Insider Tyler Dylan-Hyde Sells 15,000 Shares
www.americanbankingnews.com - December 28 at 4:08 PM
[$$] Celgene: Two Small-Cap Biotech Stocks Its Selling[$$] Celgene: Two Small-Cap Biotech Stocks It's Selling
finance.yahoo.com - December 27 at 5:08 PM
CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 5:08 PM
 Brokerages Expect Crispr Therapeutics AG (CRSP) to Announce -$0.74 Earnings Per Share Brokerages Expect Crispr Therapeutics AG (CRSP) to Announce -$0.74 Earnings Per Share
www.americanbankingnews.com - December 27 at 11:33 AM
Crispr Therapeutics Target of Unusually Large Options Trading (CRSP)Crispr Therapeutics Target of Unusually Large Options Trading (CRSP)
www.americanbankingnews.com - December 24 at 1:20 AM
Crispr Therapeutics (CRSP) Research Coverage Started at Piper Jaffray CompaniesCrispr Therapeutics (CRSP) Research Coverage Started at Piper Jaffray Companies
www.americanbankingnews.com - December 22 at 10:56 AM
Crispr Therapeutics (CRSP) Earns "Hold" Rating from OppenheimerCrispr Therapeutics (CRSP) Earns "Hold" Rating from Oppenheimer
www.americanbankingnews.com - December 21 at 10:38 AM
Insider Selling: Crispr Therapeutics AG (CRSP) Insider Sells 15,000 Shares of StockInsider Selling: Crispr Therapeutics AG (CRSP) Insider Sells 15,000 Shares of Stock
www.americanbankingnews.com - December 19 at 5:56 PM
Vertex Pharma (VRTX) CRISPR Therapeutics (CRSP) to Co-Develop and Co ...Vertex Pharma (VRTX) CRISPR Therapeutics (CRSP) to Co-Develop and Co ...
www.streetinsider.com - December 12 at 6:03 PM
Crispr Therapeutics AG (CRSP) Expected to Post Quarterly Sales of $2.10 MillionCrispr Therapeutics AG (CRSP) Expected to Post Quarterly Sales of $2.10 Million
www.americanbankingnews.com - December 12 at 12:56 PM
Vertex, CRISPR Therapeutics To Co-develop And Co-commercialize CTX001Vertex, CRISPR Therapeutics To Co-develop And Co-commercialize CTX001
www.nasdaq.com - December 12 at 9:42 AM

SEC Filings

Crispr Therapeutics (NASDAQ:CRSP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Crispr Therapeutics (NASDAQ:CRSP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Crispr Therapeutics (NASDAQ CRSP) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.